Efficacy of sequential TACE on primary hepatocellular carcinoma with microvascular invasion after radical resection: a systematic review and meta-analysis

Table 1 Baseline characteristics of included studies for meta-analysis

First author, year	Groups	No. of cases	Sex (male/female)	Diameter of tumor (< 5 cm/ ≥ 5 cm)	Complete tumor capsule (yes/no)	Differentiated degree (1–2/3–4)	NOS score
Wei W, 2019 [17]	HR-TACE	116	106/10	0/116	NA	NA	6
Wei W, 2019 [17]	HR	118	106/12	0/118	NA	NA	6
Tian BY, 2018 [18]	HR-TACE	95	84/11	44/51	55/40	53/42	8
Tian BY, 2018 [18]	HR	205	177/28	89/116	123/82	107/98	8
Liu JH, 2016 [19]	HR-TACE	137	125/12	5.00 ± 1.30	87/50	75/62	7
Liu JH, 2016 [19]	HR	159	134/25	8.00 ± 3.80	140/19	102/57	7
Liu ZY, 2017 [20]	HR-TACE	62	90/17	6.30 ± 2.27	56/6	24/38	6
Liu ZY, 2017 [20]	HR	45	90/17	6.50 ± 2.41	40/5	15/30	6
Shen PC, 2020 [21]	HR-TACE	52	37/15	27/25	24/28	20/32	7
Shen PC, 2020 [21]	HR	49	36/13	30/19	21/28	23/26	7
Qi YP, 2019 [22]	HR-TACE	91	78/13	27/25	59/32	NA	7
Qi YP, 2019 [22]	HR	109	93/16	30/19	61/48	NA	7
Li KW, 2012 [23]	HR-TACE	35	39/2	14/21	25/10	24/11	7
Li KW, 2012 [23]	HR	41	32/3	15/26	28/13	30/11	7
Ye JZ, 2017 [24]	HR-TACE	86	75/11	41/45	51/35	49/37	9
Ye JZ, 2017 [24]	HR	174	150/24	76/98	105/69	91/83	9
Wang L, 2020 [25]	HR-TACE	199	176/23	85/114	134/65	184/15	8
Wang L, 2020 [25]	HR	199	173/26	83/116	137/62	184/15	8
Wang H, 2018 [26]	HR-TACE	44	42/2	3.84 ± 1.27	31/13	1/43	9
Wang H, 2018 [26]	HR	84	76/8	3.83 ± 1.09	50/34	6/78	9
Sun JJ, 2016 [27]	HR-TACE	137	120/17	6.51 ± 0.27	11/126	13/124	9
Sun JJ, 2016 [27]	HR	185	167/18	6.99 ± 0.29	17/168	10/175	9
Wang YY, 2019 [28]	HR-TACE	57	47/10	6 (2–14)	NA	41/16	7
Wang YY, 2019 [28]	HR	57	51/6	6 (2–18)	NA	41/16	7
Liu S, 2019 [29]	HR-TACE	222	193/29	111/111	99/123	147/75	8
Liu S, 2019 [29]	HR	222	193/29	101/121	105/117	131/91	8

Abbreviation: NOS Newcastle Ottawa Scale, HR-TACE cases undergoing transcatheter arterial chemoembolization after hepatectomy resection, HR cases only undergoing hepatectomy resection

ISSN: 1477-7819